What is Cantonbio?
Founded in 2016 and headquartered in Guangzhou, China, Cantonbio is a biopharmaceutical company specializing in the development and manufacturing of therapeutic recombinant proteins, including monoclonal and bispecific antibodies. The company operates with a global footprint, featuring a holding subsidiary in Switzerland and key operational units in Foshan, China. Cantonbio is committed to establishing a leading biopharmaceutical R&D and production platform in South China, equipped with a protein drug production line that adheres to stringent FDA, EMA, and Chinese cGMP standards. The company's operational philosophy is rooted in respect, openness, and pragmatism, driven by a management team comprising international experts and locally experienced professionals. A significant portion of its workforce holds advanced degrees, reflecting a strong emphasis on scientific expertise and innovation.
How much funding has Cantonbio raised?
Cantonbio has raised a total of $41M across 1 funding round:
Series C
$41M
Series C (2023): $41M with participation from Taipu Life Science Investment, SDIC Venture Capital, Chnin Financial, and Guangdong Technology Financial Group
Key Investors in Cantonbio
Taipu Life Science Investment
Taipu Life Science Investment is an entity focused on providing capital for advancements in life sciences. Their investment in Cantonbio suggests a strategic interest in the antibody and protein therapeutics market.
SDIC Venture Capital
SDIC Venture Capital specializes in venture capital management, focusing on advanced manufacturing, electronic information, material energy, and biomedicine sectors. The company offers various investment strategies and manages multiple funds aimed at fostering innovation and growth in these industries. Their intended clients include startups and enterprises seeking investment to enhance their technological capabilities and market reach. Through their investment projects, they aim to contribute to the development of cutting-edge technologies and sustainable solutions.
Chnin Financial
Chnin Financial is likely a financial institution or investment firm that provides backing for companies in strategic sectors. Their participation indicates confidence in Cantonbio's business model and market potential.
What's next for Cantonbio?
The recent major strategic investment signals a pivotal growth phase for Cantonbio, likely enabling the company to accelerate its R&D pipeline, expand its manufacturing capacity, and potentially pursue further international market penetration. This capital infusion is expected to bolster its efforts in bringing novel antibody-based therapies to market and solidify its position as a key player in the biopharmaceutical industry. The company's focus on high-standard production lines suggests a strategic aim to capture a larger share of the global biologics market.
See full Cantonbio company page
